Abstract
Breast cancer remains a challenging disease globally due to its heterogeneity and complexity, with an annual increase rate of 3.1%. Cytochrome P450 2E1 (CYP2E1) rs2031920 and rs3813867 polymorphisms that reside in the 5’-flanking promoter region of the gene are in a complete linkage disequilibrium and have been associated with breast cancer risk, but the findings are inconsistent and inconclusive. Therefore, we investigated the association of the CYP2E1 rs2031920 and rs3813867 polymorphisms with the risk of breast cancer through a meta-analysis. After literature search, eight eligible studies were included in this meta-analysis with a total of 3650 breast cancer cases and 3607 controls. Our meta-analysis revealed no significant association of the CYP2E1 rs2031920 and rs3813867 polymorphisms with breast cancer risk in all comparison models including the allelic (OR = 0.968, 95% CI = 0.855-1.097; p = 0.612), heterozygous (OR = 1.003, 95% CI = 0.869-1.159; p = 0.963), homozygous (OR = 0.792, 95% CI = 0.519-1.207; p = 0.278), dominant (OR = 0.987, 95% CI = 0.858-1.134; p = 0.851), and recessive (OR = 1.265, 95% CI = 0.831-1.924; p = 0.273). In conclusion, this meta-analysis suggests that the CYP2E1 rs2031920 and rs3813867 polymorphisms are not associated with the risk of breast cancer.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asia Pacific Journal of Molecular Biology and Biotechnology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
